Asthma and COPD Drugs Market by Diseases (Asthma and COPD) and Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, and Others.): Global Opportunity Analysis and Industry Forecast, 2021––2030 The global Asthma and COPD Drugs Market Size was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64% from 2021 to 2030.
Download Sample: https://www.alliedmarketresearch.com/request-sample/311
The asthma and COPD can be prevented and treated with drugs such as corticosteroids, short-acting beta agonists, and anticholinergic drugs. In the acute asthmatic attack, patient feels difficulty to breathe due to sudden narrowing of bronchi, generally due to allergens. In acute asthmatic attack, bronchodilators give quick relief and can be life saving for patients.
The COVID-19 outbreak is anticipated to have a negative impact on the growth of the asthma and COPD drugs market as most hospitals are not operating due to COVID-19 and the ongoing lockdowns in many countries. The COVID-19 virus has serious and life-threatening impact on patients with respiratory disorders. However, a huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for the patient diagnosed with COVID-19, and this is expected to increase the diagnosis and treatment of respiratory diseases, which contributes in the market growth.
Key Findings Of Study
- On the basis of diseases, the asthma segment was the highest contributor to the market in 2020.
- On the basis of medication class, combination drug segment dominated the market in 2020.
- On the basis of region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Request Customization: https://www.alliedmarketresearch.com/request-for-customization/311
Key Market Segments
- BY DISEASES
- Asthma
- COPD
- BY MEDICATION CLASS
- Combination Drugs
- Short Acting Beta Agonists (SABA)
- Long Acting Beta Agonists (LABA)
- Leukotriene Antagonists (LTA)
- Anticholinergics
- Others
Key Market Players
- Abbott Laboratories
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Glaxosmithkline Plc
- Hoffmann-La Roche Ltd
- Novartis AG
- Organon
- Sanofi
- Teva Pharmaceutical Industries Ltd
- Vectura Group Plc
Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/311
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.